UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 31,866 Shares of IDEAYA Biosciences, Inc. $IDYA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 18.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 143,285 shares of the company’s stock after selling 31,866 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in IDEAYA Biosciences were worth $5,340,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in shares of IDEAYA Biosciences in the second quarter valued at $331,452,000. Jupiter Topco LLC bought a new stake in shares of IDEAYA Biosciences during the second quarter worth about $319,728,000. Janus Henderson Group PLC increased its position in shares of IDEAYA Biosciences by 1.1% during the first quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after acquiring an additional 78,797 shares in the last quarter. State Street Corp raised its holdings in shares of IDEAYA Biosciences by 27.6% in the 4th quarter. State Street Corp now owns 4,134,641 shares of the company’s stock worth $142,935,000 after acquiring an additional 893,707 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its holdings in shares of IDEAYA Biosciences by 10.5% in the 4th quarter. Baker BROS. Advisors LP now owns 3,618,826 shares of the company’s stock worth $125,103,000 after acquiring an additional 343,382 shares during the last quarter. Institutional investors own 98.29% of the company’s stock.

Insider Buying and Selling at IDEAYA Biosciences

In related news, CAO Andres Ruiz Briseno sold 9,550 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total transaction of $382,095.50. Following the completion of the transaction, the chief accounting officer owned 26,466 shares in the company, valued at approximately $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IDYA shares. Citizens Jmp reiterated a “market outperform” rating and set a $42.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Jefferies Financial Group reissued a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research report on Friday, May 22nd. Wall Street Zen downgraded IDEAYA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.46.

IDEAYA Biosciences Trading Down 2.6%

Shares of IDEAYA Biosciences stock opened at $38.84 on Wednesday. The business’s fifty day simple moving average is $37.70 and its 200 day simple moving average is $33.59. IDEAYA Biosciences, Inc. has a 12 month low of $23.53 and a 12 month high of $42.68. The firm has a market capitalization of $3.41 billion, a P/E ratio of -20.02 and a beta of -0.07.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The business had revenue of $8.86 million during the quarter, compared to the consensus estimate of $8.02 million. During the same quarter last year, the company earned ($0.88) EPS. The firm’s revenue for the quarter was up 8800.0% compared to the same quarter last year. Analysts predict that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.